The twisting journey of Pretzel Therapeutics’ top brass appears to have come full circle, with the biotech subsuming the very ...
The table below is a review of notable updates that occurred in November 2025 for investigational products in development (not an inclusive list). Click on the status ...
A Q&A With Rajesh Gandhi, MD. GANDHI: The main reasons patients and their clinicians consider switching are to simplify treatment, reduce drug interactions, and mitigate long-term safety risks. In my ...
Partnership delivers advanced reverse transcriptase technology to enhance sensitivity, robustness and reproducibility of molecular analysis in clinical, applied and pharmaceutical applications MADISON ...
Our genomes are peppered with DNA segments called retrotransposons that can move from place to place. When unleashed, some can kill nerves and promote inflammation — a discovery that may inspire ...
Meeting UNAIDS’ “95/95/95” targets for 2025—95% of people with HIV knowing their status, 95% of those who know their status on treatment, and 95% of people on treatment having a suppressed viral ...
A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback